Market Place
Sourcing Support
Qnovia Raises $16M For RespiRx™ Nicotine Inhaler Development
10 Dec 2024 //
PR NEWSWIRE
Qnovia CEO Speaks At FDA And NIH Meeting On Smoking Cessation
21 Oct 2024 //
PR NEWSWIRE
Qnovia, Inc. Announces FDA Clearance for RespiRx™ Nicotine Inhaler
01 Oct 2024 //
PR NEWSWIRE
Developers of vapes for migraine, asthma will need to win over sceptics
08 Aug 2024 //
REUTERS
Qnovia, Inc. Appoints Four New Members to Advisory Board
09 Apr 2024 //
BUSINESSWIRE
Qnovia, Inc. announces positive results from study of lead asset QN-01
29 Nov 2023 //
BUSINESSWIRE
Qnovia Enters Collaboration with University of Virginia for Drug Candidates
19 Oct 2023 //
BUSINESSWIRE
Qnovia to Present at Gilmartin Group Private Company Showcase
13 Apr 2023 //
BUSINESSWIRE
Qnovia Announces Mitch Zeller, as Policy and Regulatory Strategy Advisor
04 Apr 2023 //
BUSINESSWIRE
Qnovia to Pursue UK Approval for Lead QN-01 in Nicotine Replacement Therapy
08 Nov 2022 //
BAKERSFIELD
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.